<DOC>
	<DOCNO>NCT00894413</DOCNO>
	<brief_summary>The purpose trial determine whether Cialis ( tadalafil ) administer head neck squamous cell cancer patient augments immune response .</brief_summary>
	<brief_title>A Trial Tadalafil Patients With Squamous Cell Carcinoma Upper Aero Digestive Tract</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . Histologically confirm , previously untreated invasive head neck squamous cell carcinoma OR histologically confirm yet treat recurrent head neck squamous cell carcinoma ( must least 3 month diagnosis completion treatment primary disease last recurrence ) . 2 . Disease location amenable biopsy outpatient clinical set operative biopsy within routine accept schedule practice clinical care 3 . No medical contraindication biopsy target lesion . 4 . ECOG performance status 01 5 . Required laboratory data ( obtain within 4 week initiation ) : Platelets &gt; 75,000/mm³ Calculated Creatinine Clearance ( CRCL ) &gt; 60 mL/min iii . Total serum bilirubin &lt; 1.5 mg/dL . No intercurrent illness likely prevent protocol therapy surgical resection 6 . Patients history curatively treated malignancy must diseasefree survival prognosis exceed five year . 7 . Female patient must pregnant breast feeding . A negative pregnancy test require within 14 day randomization woman childbearing potential . 8 . Willingness ability give sign write informed consent . 1 . Known severe hypersensitivity tadalafil excipients product 2 . Patients concurrent malignancy history previous malignancy treat curative therapy within last 3 month ( squamous/basal cell cancer skin cervical cancer ) survival prognosis &lt; 5 year . 3 . Treatment nonapproved investigational drug within 30 day day 1 trial treatment . 4 . Incomplete heal previous oncologic major surgery . 5 . Pregnancy breast feeding ( woman childbearing potential ) . 6 . As judged investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) . 7 . Evidence significant clinical disorder laboratory find make undesirable subject participate trial . 8 . Current therapy ketoconazole oral antifungal therapy . 9 . History significant hypotensive episode require hospitalization . 10 . A history acute myocardial infarction within prior 3 month , uncontrolled angina , 11 . Uncontrolled arrhythmia , uncontrolled congestive heart failure 12 . Age &lt; 18 13 . History follow cardiac condition : Angina require treatment longacting nitrate . Angina require treatment shortacting nitrate within 90 day plan tadalafil administration . Unstable angina within 90 day visit 1 ( Braunwald 1989 ) . Positive cardiac stress test without document evidence subsequent , effective cardiac intervention . 14 . History follow coronary condition within 90 day plan tadalafil administration : Myocardial Infarction . Coronary artery bypass graft surgery . Percutaneous coronary intervention ( example , angioplasty stent placement ) . Any evidence heart disease ( NYHA≥Class III define Protocol Attachment LVHG.3 ) within 6 month plan tadalafil administration 15 . Current treatment nitrate . 16 . Current systemic treatment potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor ketoconazole ritonavir . 17 . Received treatment within last 30 day drug device receive regulatory approval indication time Visit 1 . 18 . Prior chronic immune suppressive state ( AIDS , immunosuppressive therapy ) . 19 . History hypotension and/or blindness prior treatment Tadalafil PDE5 inhibitor . 20. prior history nonarterial ischemic optic retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>